Abstract
Osteoarthritis (OA) is a common disease in the practice of doctors of various specialties. Leading international organizations regularly update recommendations for the treatment of patients with this disease. The viewpoints of experts differ concerning various interventions. The article issues the use of a drug group — Symptomatic Slow-Acting Drug in Osteoarthritis (SYSADOA), such as glucosamine and chondroitin sulfate (CS). To date, data on the efficacy and good tolerability of these drugs have been accumulating, which is important due to the significant comorbidity in patients with OA. The results of numerous studies reviewed by the authors have suggested a possible mechanism of analgesic and anti-inflammatory action of chondroitin sulfate (CS). In the leading international and national recommendations, CS is included in the treatment regimens of patients with OA, with the clarification that the prescription form has an advantage. The recommendations of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, (ESCEO) in 2019 strongly recommended the use of high-quality CS as a long-term background treatment. KEYWORDS: osteoarthritis, recommendations, symptomatic slow-acting drug, chondroitin sulfate. FOR CITATION: Yakupova S.P., Fedorova E.A. Chondroitin sulfate in the treatment of osteoarthritis. Russian Medical Inquiry. 2022;6(3):148– 152 (in Russ.). DOI: 10.32364/2587-6821-2022-6-3-148-152.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
